摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1'-((2-(trimethylsilyl)ethoxy)methyl)-1',4',5',7'-tetrahydrospiro[cyclopropane-1,6'-indazole]-3'-carboxylic acid | 1557247-80-9

中文名称
——
中文别名
——
英文名称
1'-((2-(trimethylsilyl)ethoxy)methyl)-1',4',5',7'-tetrahydrospiro[cyclopropane-1,6'-indazole]-3'-carboxylic acid
英文别名
1-(2-trimethylsilylethoxymethyl)spiro[5,7-dihydro-4H-indazole-6,1'-cyclopropane]-3-carboxylic acid
1'-((2-(trimethylsilyl)ethoxy)methyl)-1',4',5',7'-tetrahydrospiro[cyclopropane-1,6'-indazole]-3'-carboxylic acid化学式
CAS
1557247-80-9
化学式
C16H26N2O3Si
mdl
——
分子量
322.48
InChiKey
BNMSQTNPWSASKX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    460.7±45.0 °C(Predicted)
  • 密度:
    1.22±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.16
  • 重原子数:
    22
  • 可旋转键数:
    6
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.75
  • 拓扑面积:
    64.4
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1'-((2-(trimethylsilyl)ethoxy)methyl)-1',4',5',7'-tetrahydrospiro[cyclopropane-1,6'-indazole]-3'-carboxylic acid1-苄基-1H-吡唑-4-胺 在 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 N,N-二异丙基乙胺 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 生成
    参考文献:
    名称:
    Property- and Structure-Guided Discovery of a Tetrahydroindazole Series of Interleukin-2 Inducible T-Cell Kinase Inhibitors
    摘要:
    Interleukin-2 inducible T-cell kinase (ITK), a member of the Tec family of tyrosine kinases, plays a major role in T-cell signaling downstream of the T-cell receptor (TCR), and considerable efforts have been directed toward discovery of ITK-selective inhibitors as potential treatments of inflammatory disorders such as asthma. Using a previously disclosed indazole series of inhibitors as a starting point, and using X-ray crystallography and solubility forecast index (SFI) as guides, we evolved a series of tetrahydroindazole inhibitors with improved potency, selectivity, and pharmaceutical properties. Highlights include identification of a selectivity pocket above the ligand plane, and identification of appropriate lipophilic substituents to occupy this space. This effort culminated in identification of a potent and selective ITK inhibitor (GNE-9822) with good ADME properties in preclinical species.
    DOI:
    10.1021/jm500550e
  • 作为产物:
    参考文献:
    名称:
    Property- and Structure-Guided Discovery of a Tetrahydroindazole Series of Interleukin-2 Inducible T-Cell Kinase Inhibitors
    摘要:
    Interleukin-2 inducible T-cell kinase (ITK), a member of the Tec family of tyrosine kinases, plays a major role in T-cell signaling downstream of the T-cell receptor (TCR), and considerable efforts have been directed toward discovery of ITK-selective inhibitors as potential treatments of inflammatory disorders such as asthma. Using a previously disclosed indazole series of inhibitors as a starting point, and using X-ray crystallography and solubility forecast index (SFI) as guides, we evolved a series of tetrahydroindazole inhibitors with improved potency, selectivity, and pharmaceutical properties. Highlights include identification of a selectivity pocket above the ligand plane, and identification of appropriate lipophilic substituents to occupy this space. This effort culminated in identification of a potent and selective ITK inhibitor (GNE-9822) with good ADME properties in preclinical species.
    DOI:
    10.1021/jm500550e
点击查看最新优质反应信息

文献信息

  • PYRAZOLE CARBOXAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
    申请人:Genentech, Inc.
    公开号:US20150158851A1
    公开(公告)日:2015-06-11
    Provided herein are compounds of formula (AA): stereoisomers or a pharmaceutically acceptable salt thereof, wherein A, R a , p, R 5 and R 6 are defined herein, compositions including the compounds and methods of manufacturing and using the compounds for the treatment of diseases.
    本文提供了式(AA)的化合物:其立体异构体或其药学上可接受的盐,其中A、Ra、p、R5和R6在此定义,包括该化合物的组合物以及制造和使用该化合物治疗疾病的方法。
  • [EN] BICYCLIC LACTAMS AND METHODS OF USE THEREOF<br/>[FR] LACTAMES BICYCLIQUES ET LEURS MÉTHODES D'UTILISATION
    申请人:GENENTECH INC
    公开号:WO2017004500A9
    公开(公告)日:2017-11-30
查看更多